Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds

Oncotarget

Volumn 7, Issue 12, 2016, Pages 13965-13975

  Liu, Li Juan ^a   He, Bingyong ^b   Miles, Jennifer A ^c   Wang, Wanhe ^b   Mao, Zhifeng ^b   Che, Weng Ian ^a   Lu, Jin Jian ^a   Chen, Xiu Ping ^a   Wilson, Andrew J ^c   Ma, Dik Lung ^b   Leung, Chung Hang ^a  

^a University of Macau   (Macao)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

HDM2; Metal based inhibitor; P53; Protein protein interaction

Indexed keywords

1 PHENYL 1H PYRAZOLE (2, 2' BIPYRIDINE),2,2' BIPYRIDINEBIS(1 PHENYL 1H PYRAZOLE)IRIDIUM COMPOUND; 2 (2,4 DIFLUOROPHENYL)PYRIDINE(11,12 DICHLORODIPYRIDO[3,2 A:2',3' C]PHENAZINE),11,12 DICHLORODIPYRIDO[3,2 A:2',3' C]PHENAZINEBIS(2 (2,4 DIFLUOROPHENYL)PYRIDINE)IRIDIUM COMPOUND; 2 (4 ETHYLPHENYL)PYRIDINE(4, 7 DICHLORO 1,10 PHENANTHROLINE),4,7 DICHLORO 1,10 PHENANTHROLINEBIS(2(4 ETHYLPHENYL)PYRIDINE)IRIDIUM COMPOUND; 2 (4 ETHYLPHENYL)PYRIDINE(4,4' DI TERT BUTYL 2, 2' BIPYRIDINE),4,4' DI TERT BUTYL 2,2' BIPYRIDINEBIS(2 (4 ETHYLPHENYL)PYRIDINE)IRIDIUM COMPOUND; 2 PHENYLBENZO[D]THIAZOLE(5 CHLORO 1,10 PHENANTHROLINE),5 CHLORO 1,10 PHENANTHROLINEBIS(2 PHENYLBENZO[D]THIAZOLE)IRIDIUM COMPOUND; 2 PHENYLQUINOLINE(PYRAZINO[2,3 F][1,10]PHENANTHROLINE), PYRAZINO[2,3 F][1,10]PHENANTHROLINEBIS(2 PHENYLQUINOLINE)IRIDIUM COMPOUND; ANTINEOPLASTIC AGENT; IRIDIUM COMPLEX; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; IRIDIUM; MDM2 PROTEIN, HUMAN; ORGANOMETALLIC COMPOUND; TP53 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MELANOMA CELL; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN DOMAIN; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; HUMANS; IRIDIUM; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84971617583     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7369     Document Type: Article

References (51)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408: 307-310.
2. Carry JC, Garcia-Echeverria C. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic. Bioorg Med Chem Lett. 2013; 23: 2480-2485.
3. Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res. 2003; 1: 1009-1016.
4. Chene P. Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nat Rev Cancer. 2003; 3: 102-109.
5. Chene P. Inhibition of the p53-MDM2 interaction: Targeting a protein-protein interface. Mol Cancer Res. 2004; 2: 20-28.
6. Fischer PM, Lane DP. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci. 2004; 25:343-346.
7. Vu B, Wovkulich P, Pizzolato G, Lovey A, Ding QJ, Jiang N, Liu JJ, Zhao CL, Glenn K, Wen Y, Tovar C, Packman K, Vassilev L,et al. Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development. Acs Med Chem Lett. 2013; 4: 466-469.
8. Y Z, D B, S W. Small Molecule inhibitors of MDM2-p53 and MDMX-p53 interaction as new cancer therapeutics. BioDiscovery. 2013; 4-18.
9. Shangary S, Wang SM. Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy. Annu Rev Pharmacol Toxicol. 2009; 49: 223-241.
10. Leung CH, He HZ, Liu LJ, Wang MD, Chan DSH, Ma DL. Metal complexes as inhibitors of transcription factor activity. Coord Chem Rev. 2013; 257: 3139-3151.
11. Leung CH, Lin S, Zhong HJ, Ma DL. Metal complexes as potential modulators of inflammatory and autoimmune responses. Chem Sci. 2015; 6: 871-884.
12. Meier SM, Novak MS, Kandioller W, Jakupec MA, Roller A, Keppler BK, Hartinger CG. Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru (arene) anticancer agent. Dalton Trans. 2014; 43: 9851-9855.
13. Serebryanskaya TV, Lyakhov AS, Ivashkevich LS, Schur J, Frias C, Prokop A, Ott I. Gold(I) thiotetrazolates as thioredoxin reductase inhibitors and antiproliferative agents. Dalton Trans. 2015; 44: 1161-1169.
14. Leonidova A, Pierroz V, Adams LA, Barlow N, Ferrari S, Graham B, Gasser G. Enhanced Cytotoxicity through Conjugation of a "Clickable" Luminescent Re(I) Complex to a Cell-Penetrating Lipopeptide. ACS Med Chem Lett. 2014; 5: 809-814.
15. Rilak A, Bratsos I, Zangrando E, Kljun J, Turel I, Bugarcic ZD, Alessio E. New Water-Soluble Ruthenium(II) Terpyridine Complexes for Anticancer Activity: Synthesis, Characterization, Activation Kinetics, and Interaction with Guanine Derivatives. Inorg Chem. 2014; 53: 6113-6126.
16. McConnell AJ, Lim MH, Olmon ED, Song H, Dervan EE, Barton JK. Luminescent Properties of Ruthenium(II) Complexes with Sterically Expansive Ligands Bound to DNA Defects. Inorg Chem. 2012; 51: 12511-12520.
17. Ma DL, He HZ, Leung KH, Chan DSH, Leung CH. Bioactive Luminescent Transition-Metal Complexes for Biomedical Applications. Angew Chem Int Ed. 2013; 52: 7666-7682.
18. Barragan F, Lopez-Senin P, Salassa L, Betanzos-Lara S, Habtemariam A, Moreno V, Sadler PJ, Marchan V. Photocontrolled DNA Binding of a Receptor-Targeted Organometallic Ruthenium(II) Complex. J Am Chem Soc. 2011; 133: 14098-14108.
19. Hindo SS, Mancino AM, Braymer JJ, Liu YH, Vivekanandan S, Ramamoorthy A, Lim MH. Small Molecule Modulators of Copper-Induced A beta Aggregation. J Am Chem Soc. 2009; 131: 16663-16665.
20. Muldoon J, Ashcroft AE, Wilson AJ. Selective Protein-Surface Sensing Using Ruthenium(II) Tris(bipyridine) Complexes. Chem-Eur J. 2010; 16: 100-103.
21. Leung KH, He HZ, He BY, Zhong HJ, Lin S, Wang YT, Ma DL, Leung CH. Label-free luminescence switch-on detection of hepatitis C virus NS3 helicase activity using a G-quadruplex-selective probe. Chem Sci. 2015; 6: 2166-2171.
22. Lu LH, Chan DSH, Kwong DWJ, He HZ, Leung CH,Ma DL. Detection of nicking endonuclease activity using a G-quadruplex-selective luminescent switch-on probe. Chem Sci. 2014; 5: 4561-4568.
23. Leung CH, Chan DSH, He HZ, Cheng Z, Yang H, Ma DL. Luminescent detection of DNA-binding proteins. Nucleic Acids Res. 2012; 40: 941-955.
24. Ma DL, Chan DSH, Leung CH. Group 9 Organometallic Compounds for Therapeutic and Bioanalytical Applications. Acc Chem Res. 2014; 47: 3614-3631.
25. Lo KKW, Zhang KY. Iridium(III) complexes as therapeutic and bioimaging reagents for cellular applications. Rsc Adv. 2012; 2: 12069-12083.
26. Leung CH, Liu LJ, Lu LH, He BY, Kwong DWJ, Wong CY, Ma DL. A metal-based tumour necrosis factor-alpha converting enzyme inhibitor. Chem Commun. 2015; 51: 3973-3976.
27. Zhong HJ, L. L, Leung KH, Wong CL, Peng C, Yan SC, Ma DL, Cai Z, Wang HM, Leung CH. An iridium(III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent. Chem Sci. 2015; 6: 5400-5408.
28. Liu LJ, Lu L, Zhong HJ, He B, Kwong D, Ma DL, Leung CH. An Iridium(III) Complex Inhibits JMJD2 Activities and Acts as A Potential Epigenetic Modulator. J Med Chem. 2015; 58: 6697-6703.
29. Kastl A, Wilbuer A, Merkel AL, Feng L, Di Fazio P, Ocker M, Meggers E. Dual anticancer activity in a single compound: visible-light-induced apoptosis by an antiangiogenic iridium complex. Chem Commun. 2012; 48: 1863-1865.
30. Hearn JM, Romero-Canelon I, Qamar B, Liu Z, Hands-Portman I, Sadler PJ. Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis. ACS Chem Biol. 2013; 8: 1335-1343.
31. Geldmacher Y, Oleszak M, Sheldrick WS. Rhodium(III) and iridium(III) complexes as anticancer agents. Inorg Chim Acta. 2012; 393: 84-102.
32. Leung CH, Zhong HJ, Yang H, Cheng Z, Chan DSH, Ma VPY, Abagyan R, Wong CY, Ma DL. A Metal-Based Inhibitor of Tumor Necrosis Factor-alpha. Angew Chem Int Ed. 2012; 51: 9010-9014.
33. Barnard A, Long K, Martin HL, Miles JA, Edwards TA, Tomlinson DC, Macdonald A, Wilson AJ. Selective and Potent Proteomimetic Inhibitors of Intracellular Protein-Protein Interactions. Angew Chem Int Ed. 2015; 54: 2960-2965.
34. Machleidt T, Woodroofe CC, Schwinn MK, Mendez J, Robers MB, Zirnmerman K, Otto P, Daniels DL, Kirkland TA, Wood KV. NanoBRET-A Novel BRET Platform for the Analysis of Protein-Protein Interactions. ACS Chem Biol. 2015; 10: 1797-1804.
35. Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, et al. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem. 2015; 58: 6348-6358.
36. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003; 22: 9030-9040.
37. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005; 65: 3980-3985.
38. Kitagaki J, Agama KK, Pommier Y, Yang YL, Weissman AM. Targeting tumor cells expressing p53with a water-soluble inhibitor of Hdm2. Mol Cancer Ther. 2008; 7: 2445-2454.
39. Koblish HK, Zhao SY, Franks CF, Donatelli RR, Tominovich RM, LaFrance LV, Leonard KA, Gushue JM, Parks DJ, Calvo RR, Milkiewicz KL, Marugan JJ, Raboisson P, et al. Benzodiazepinedione inhibitors of the Hdm2 : p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther. 2006; 5: 160-169.
40. Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014; 13: 217-236.
41. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003; 1: 1001-1008.
42. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303: 844-848.
43. Patel S, Player MR. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Inv Drug. 2008; 17: 1865-1882.
44. Leao M, Pereira C, Bisio A, Ciribilli Y, Paiva AM, Machado N, Palmeira A, Fernandes MX, Sousa E, Pinto M, Inga A, Saraiva L. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. Biochem Pharmacol. 2013; 85: 1234-1245.
45. Brown CJ, Quah ST, Jong J, Goh AM, Chiam PC, Khoo KH, Choong ML, Lee MA, Yurlova L, Zolghadr K, Joseph TL, Verma CS, Lane DP. Stapled Peptides with Improved Potency and Specificity That Activate p53. ACS Chem Biol. 2013; 8: 506-512.
46. Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To KH, Olson KA, Kesavan K, Gangurde P, Mukherjee A, Baker T, Darlak K, Elkin C, et al. Stapled alpha-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A. 2013; 110: E3445-E3454.
47. Tamayo AB, Garon S, Sajoto T, Djurovich PI, Tsyba IM, Bau R, Thompson ME. Cationic bis-cyclometalated iridium(III) diimine complexes and their use in efficient blue, green, and red electroluminescent devices. Inorg Chem. 2005; 44: 8723-8732.
48. Plante JP, Burnley T, Malkova B, Webb ME, Warriner SL, Edwards TA, Wilson AJ. Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction. Chem Commun. 2009; 5091-5093.
49. Barnard A, Long K, Yeo DJ, Miles JA, Azzarito V, Burslem GM, Prabhakaran P, Edwards TA, Wilson AJ. Orthogonal functionalisation of alpha-helix mimetics. Org Biomol Chem. 2014; 12: 6794-6799.
50. Ma DL, Liu LJ, Leung KH, Chen YT, Zhong HJ, Chan DSH, Wang HMD, Leung CH. Antagonizing STAT3 Dimerization with a Rhodium(III) Complex. Angew Chem Int Ed. 2014; 53: 9178-9182.
51. Liu LJ, Leung KH, Chan DSH, Wang YT, Ma DL, Leung CH. Identification of a natural product-like STAT3dimerization inhibitor by structure-based virtual screening. Cell Death Dis. 2014; 5: e1293.